**CLAIMS**

What is claimed is:

1. A method of treating with oxybutynin a human subject having overactive bladder, while minimizing an anticholinergic or antimuscarinic adverse drug experience associated with said oxybutynin treatment therapy comprising the step of:

administering a composition comprising oxybutynin to said subject as a transdermal patch having a size of from 13 $cm^2$ to 39 $cm^2$, to provide a plasma area under the curve (AUC) ratio of oxybutynin to an oxybutynin metabolite of from about 0.5:1 to about 5:1, wherein the transdermal patch optionally includes a permeation enhancer.

2. The method of claim 1, wherein the AUC ratio of oxybutynin to an oxybutynin metabolite is from about 1:1 to about 5:1.

3. The method of claim 2, wherein the AUC ratio of oxybutynin to an oxybutynin metabolite is from about 0.8:1 to about 1.5:1.

4. The method of claim 1, wherein the metabolite of oxybutynin is N-desethyloxybutynin.

5. The method of claim 4, wherein the N-desethyloxybutynin is (R)-N-desethyloxybutynin, (S)-N-desethyloxybutynin or a combination thereof.

6. The method of claim 1, wherein the oxybutynin is a mixture of R-oxybutynin and S-oxybutynin.

7. The method of claim 6, wherein the oxybutynin is R-oxybutynin.

8. The method of claim 1, wherein the patch size is 13 $cm^2$.

9. The method of claim 1, wherein the patch size is 39 $cm^2$.

10. The method of claim 1, further comprising concurrently administering a plurality of patches to said subject.

11. The method of 10, wherein the plurality of patches is a plurality of 13 $cm^2$ patches.

12. An article of manufacture for transdermal application comprising:

a transdermal patch including a composition of oxybutynin and optionally a permeation enhancer for administration to a human subject, wherein the patch provides, upon administration to said subject at a size of from 13 $cm^2$ to 39 $cm^2$, a plasma AUC ratio of oxybutynin to an oxybutynin metabolite from about 0.5:1 to about 5:1, and wherein said patch minimizes an anticholinergic or antimuscarinic adverse drug experience associated with the administration of oxybutynin.

13. The article of manufacture of claim 12, wherein the AUC ratio of oxybutynin to an oxybutynin metabolite is from about 1:1 to about 5:1.

14. The article of manufacture of claim 13, wherein the AUC ratio of oxybutynin to an oxybutynin metabolite is from about 0.8:1 to about 1.5:1.

15. The article of manufacture of claims 12, wherein the metabolite of oxybutynin is N-desethyloxybutynin.

16. The article of manufacture of claim 15, wherein the N-desethyloxybutynin is (R)-N-desethyloxybutynin, (S)-N-desethyloxybutynin or a combination thereof.

17. The article of manufacture of claim 12, wherein the oxybutynin is a mixture of R-oxybutynin and S-oxybutynin.

18. The article of manufacture of claim 17, wherein the oxybutynin is R-oxybutynin.

19. The article of manufacture of claim 12, wherein the patch size is 13 $cm^2$.

20. The article of manufacture of claim 12, wherein the patch size is 39 $cm^2$.

21. The article of manufacture of claim 12, further comprising concurrently administering a plurality of patches to said subject.

22. The article of manufacture of claim 21, wherein the plurality of patches is a plurality of 13 $cm^2$ patches.